XCath to Perform Live Telerobotic Trial Procedure at Abu Dhabi Global Healthcare Week
May 14 2024 - 9:36AM
Business Wire
Live showcase of remote robotic capability for
emergent interventional procedures
XCath, an early-stage medical device company dedicated to
expanding endovascular treatment modalities through its smart
steerable guidewires and robotic systems, will exhibit its
technology through innovation sessions at Abu Dhabi Global
Healthcare Week (ADGHW) hosted by the Abu Dhabi Department of
Health (DoH). The demonstration will include a live telerobotic
trial procedure between Abu Dhabi and South Korea on May 15th at
11:00 am GST, demonstrating the XCath platform’s potential to
support remote minimally invasive procedures for the management of
acute neurovascular conditions. Dr. Vitor Mendes Pereira, Director
of Endovascular Research and Innovation at St. Michael’s Hospital
in Toronto, Canada, will perform the live trial demonstration.
ADGHW will take place May 13-15 in Abu Dhabi, uniting global
healthcare leaders, policymakers and stakeholders to examine
worldwide trends and industry challenges.
“By enabling telerobotic procedures, we can provide a solution
for reimagining complex care,” said Eduardo Fonseca, CEO of XCath.
“Dr. Pereira is a pioneer in endovascular neurosurgery and shares
our vision for advancing telerobotic treatment options, which has
become a humanitarian and economic imperative for conditions such
as stroke. His telerobotic demonstration will show the viability of
our platform as a solution to meet the global demand for new
treatment options to expand access to care for patients
globally.”
In the session XCath will introduce the company, navigation
challenges, and an overview of its platform. XCath will also
spotlight the transformative impact of the endovascular revolution
in healthcare, illustrating how expert navigation through our
body's extensive highway of blood vessels has transformed clinical
outcomes.
“ADGHW is a tremendous opportunity for XCath to display its
concept on an international stage,” said Neeraj Agrawal, Executive
Director of Crescent Enterprises and XCath Board Member. “Crescent
Enterprises is dedicated to helping disruptive companies foster
growth and innovation in the Middle East, and XCath’s presentation
will increase awareness surrounding venture capital investments in
the area.”
Dr. Pereira performed the world’s first robotic-assisted
neurointerventional procedure in 2019, a stent-assisted coiling
procedure to treat a large basilar aneurysm. He serves as a
Professor of Surgery and Medical Imaging at the University of
Toronto and is the lead scientist of the RADIS lab, which focuses
on applying innovative technologies on the treatment of
neurovascular diseases.
For more information about ADGHW, visit https://www.adghw.com/.
To learn more about XCath, visit https://www.xcath.com/.
About XCath Founded in 2017, XCath is a dynamic startup
at the cutting edge of revolutionary medical robotics, nanorobtics
and materials science. XCath develops next-generation endovascular
robotic systems and steerable guidewires to treat life-threatening
conditions like cerebrovascular disorders. With strategically
located campuses in Houston, Texas – home to the world's largest
medical center – and Pangyo, South Korea, often referred to as the
Silicon Valley of Korea, XCath is committed to bringing its
innovative solutions to patients around the world.
The XCath steerable guidewires and endovascular robotic systems
are currently under development. They are not yet cleared for
commercial distribution in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514831209/en/
Dan Ventresca Matter Health for XCath XCath@matternow.com